Response rates of 30% have been reported in a subsequent phase II studies conducted in refractory advanced BRCA-mutant ovarian cancer [45], suggesting BRCA1-2 mutations as potential predictive biomarkers for clinical use. Here, BRCA1 is linked to ovarian cancer.